First-pass extracted concept

genetic capsid engineering

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

This review summarizes recent advances in redirecting AAV tropism toward endothelial cells (ECs) through genetic capsid engineering, peptide display, and non-genetic surface modification.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1mechanismsupports2026Source 1DOI PubMed

Genetic engineering strategies can reduce HSPG binding and hepatocyte transduction while enhancing intracellular trafficking in endothelial cells.

Quoted textsource-backed

genetic engineering strategies that reduce heparan sulfate proteoglycan (HSPG) binding and hepatocyte transduction while enhancing intracellular trafficking in ECs

Claim 2overall conclusionsupports2026Source 1DOI PubMed

Endothelial-retargeting strategies for AAV are promising for enhancing vascular tropism and transduction efficiency and may enable precise vascular gene therapies.

Quoted textsource-backed

Together, these strategies represent promising avenues for enhancing vascular tropism and transduction efficiency of modified AAVs, moving the field closer to precise vascular gene therapies.

Claim 3strategy summarysupports2026Source 1DOI PubMed

AAV tropism can be redirected toward endothelial cells through genetic capsid engineering, peptide display, and non-genetic surface modification.

Quoted textsource-backed

This review summarizes recent advances in redirecting AAV tropism toward endothelial cells (ECs) through genetic capsid engineering, peptide display, and non-genetic surface modification.